Article citationsMore>>
Melaiu, O., Mina, M., Chierici, M., Boldrini, R., Jurman, G., Romania, P., et al. (2017) PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research.
has been cited by the following article:
-
TITLE:
N-Myc Inhibition: Advances in Neuroblastoma Treatment
AUTHORS:
Md Kamrul Hasan
KEYWORDS:
Neuroblastoma, N-Myc, PI3K/mTOR, PARP1, PD-L1, HAUSP
JOURNAL NAME:
CellBio,
Vol.6 No.3,
September
30,
2017
ABSTRACT: Neuroblastoma (NBL) is one
of the most common solid tumors and around 15% of cancer mortality in children.
Amplification of the N-Myc proto-oncogene is strongly correlated with
advanced disease and poor clinical outcome in NBL. Recent studies described
that ubiquitin-specific protease 7 (USP7; also known as HAUSP) interacts with
N-Myc, induces deubiquitination and subsequent stabilization of N-Myc that
in-turn potentiates N-Myc
function, and treatment with the HAUSP inhibitor (P22077) blocked such effects.